226 related articles for article (PubMed ID: 17685891)
1. Varenicline: progress in smoking cessation treatment.
Glover ED; Rath JM
Expert Opin Pharmacother; 2007 Aug; 8(11):1757-67. PubMed ID: 17685891
[TBL] [Abstract][Full Text] [Related]
2. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
3. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Keating GM; Lyseng-Williamson KA
Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of varenicline for smoking cessation.
Hays JT; Ebbert JO; Sood A
Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
[TBL] [Abstract][Full Text] [Related]
5. Varenicline: for smoking cessation.
Rao J; Shankar PK
Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
[TBL] [Abstract][Full Text] [Related]
7. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
8. Varenicline for smoking cessation.
Tonstad S
Expert Rev Neurother; 2007 Feb; 7(2):121-7. PubMed ID: 17286546
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
[TBL] [Abstract][Full Text] [Related]
10. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
West R; Baker CL; Cappelleri JC; Bushmakin AG
Psychopharmacology (Berl); 2008 Apr; 197(3):371-7. PubMed ID: 18084743
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
[TBL] [Abstract][Full Text] [Related]
12. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
13. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
Lam S; Patel PN
Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
[TBL] [Abstract][Full Text] [Related]
14. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
Foulds J
Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
[TBL] [Abstract][Full Text] [Related]
15. [New drugs; varenicline].
van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
[TBL] [Abstract][Full Text] [Related]
16. [Varenicline - pharmacological therapy of tobacco dependence].
Tschabitscher P; Homaier I; Lichtenschopf A; Groman E
Wien Med Wochenschr; 2009; 159(1-2):17-23. PubMed ID: 19225731
[TBL] [Abstract][Full Text] [Related]
17. Varenicline: a review of its use as an aid to smoking cessation therapy.
Keating GM; Siddiqui MA
CNS Drugs; 2006; 20(11):945-60. PubMed ID: 17044731
[TBL] [Abstract][Full Text] [Related]
18. Varenicline: new treatment with efficacy in smoking cessation.
Reus VI; Obach RS; Coe JW; Faessel H; Rollema H; Watsky E; Reeves K
Drugs Today (Barc); 2007 Feb; 43(2):65-75. PubMed ID: 17353944
[TBL] [Abstract][Full Text] [Related]
19. A preliminary benefit-risk assessment of varenicline in smoking cessation.
Cahill K; Stead L; Lancaster T
Drug Saf; 2009; 32(2):119-35. PubMed ID: 19236119
[TBL] [Abstract][Full Text] [Related]
20. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
